A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

Status:Active, not recruiting
Conditions:Lung Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:October 12, 2015
End Date:June 17, 2019

Use our guide to learn which trials are right for you!

A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus
necitumumab is effective and safe in participants with stage IV squamous non-small cell lung

Inclusion Criteria:

- Have histologically or cytologically confirmed squamous NSCLC.

- Have stage IV disease at the time of study entry (American Joint Committee on Cancer
[AJCC] Staging Manual, 7th edition).

- Have measurable disease at the time of study enrollment as defined by Response
Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).

- Have tumor tissue available for biomarker analysis.

- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

- Have adequate organ functions.

Exclusion Criteria:

- Are currently enrolled in another clinical trial.

- Have received prior anticancer therapy with monoclonal antibodies, signal transduction
inhibitors, or any therapies targeting the epidermal growth factor receptor (EGFR),
vascular endothelial growth factor (VEGF), or VEGF receptor.

- Have received previous chemotherapy for advanced NSCLC. Participants who have received
adjuvant or neoadjuvant chemotherapy are eligible if the last administration of the
prior regimens occurred at least 1 year prior to study entry.

- Have undergone major surgery or received any investigational therapy in the 4 weeks
prior to study entry.

- Have undergone systemic radiotherapy within 4 weeks prior to study entry, or focal
radiotherapy within 2 weeks prior to study entry.

- Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not

- Have a history of arterial or venous embolism within 6 months prior to study entry.

- Have clinical evidence of concomitant infectious conditions.

- Have a known allergy / history of hypersensitivity reaction to any of the treatment
components, including any ingredient used in the formulation of necitumumab, or any
other contraindication to one of the administered treatments.

- Are pregnant or breastfeeding.

- Have a known history of drug abuse.

- Have a concurrent active malignancy. Participants with a history of malignancy are
eligible provided the participant has been disease-free for ≥3 years, with the
following exception: Participants with adequately treated basal or squamous cell
carcinoma of the skin, preinvasive carcinoma of the cervix, or any cancer that in the
judgment of the investigator and Lilly clinical research physician/designee may not
affect the interpretation of results (for example, prostate, bladder) are eligible.

- Have discontinued investigational product or non approved use of a drug or device from
a clinical trial within 30 days before the first day of study treatment.
We found this trial at
Orlando, Florida 32804
Principal Investigator: Tarek Mekhail
Phone: 407-898-2343
Orlando, FL
Click here to add this to my saved trials